Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Does It Have Edge In Preventing Severe Cases?

 
• By Andrew McConaghie

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Moderna's laboratories, where it began its collaboration with the NIH on its vaccine in January 2020. • Source: Moderna

More from COVID-19

More from Scrip